Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Hyperliquid (HYPE) Loses the Critical $65–$66 Level: Will Sellers Push It Lower?

Hyperliquid (HYPE) Loses the Critical $65–$66 Level: Will Sellers Push It Lower?

CryptoNewsNetCryptoNewsNet2026/07/17 19:27
By:CryptoNewsNet
Back to the list

Hyperliquid (HYPE) Loses the Critical $65–$66 Level: Will Sellers Push It Lower?

Hyperliquid (HYPE) Loses the Critical $65–$66 Level: Will Sellers Push It Lower? image 0  thenewscrypto.com 22 m
Hyperliquid (HYPE) Loses the Critical $65–$66 Level: Will Sellers Push It Lower? image 1
  • Hyperliquid has lost over 11% to $58.
  • $HYPE’s macro trend remains bearish.

Hyperliquid ($HYPE) is currently trading at $58.87, down 11.64%. Besides, the daily volume surged over 40% to $572.57 million. The volume spike during a selloff indicates an active battle between buyers and sellers at a critical level.

The token has broken below the $65–$66 resistance zone that previously acted as a floor. Moreover, losing that range puts $60 in light as the next line of defence, with $57.22 as the deeper target if sellers maintain control.

$HYPE is sitting directly on a higher-timeframe support that has repeatedly attracted buyers. The rejection from the long-term descending trendline is consistent, and sellers have defended that level twice now. But sell-side momentum is not expanding the way it did during previous pullbacks.

The asset’s bulls need to reclaim the $65–$66 neckline with conviction. Also, this is the zone that flips the momentum from corrective to recovery. Until a definitive breakout occurs, all price bounces within this formation remain insignificant.

Elevated volume at key support levels is currently preventing a definitive bearish breakdown for Hyperliquid. If that demand zone holds and absorbs the remaining sell pressure, it could set up for a sharp recovery.

Short-Term Momentum: Where Is Hyperliquid Headed Next?

The active downtrend has the potential to retrace the Hyperliquid price toward the nearest support level at $57.36. If the bearish correction strengthens, it would trigger the death cross to emerge and send the price below $55.

Upon a reversal in $HYPE momentum, the price could rise and immediately find the resistance at around $59.65. Assuming the golden cross takes place with the bulls reinforces their ground, the price would climb to the $61 mark.

Notably, RSI needs to stabilise, and MACD momentum needs to flatten before any serious trend reversal develops. The current structure does not support a bearish panic. However, a sustained bullish narrative requires a definitive breach of the descending trendline rather than a temporary intraday recovery.

Hyperliquid (HYPE) Loses the Critical $65–$66 Level: Will Sellers Push It Lower? image 2 (Source: TradingView)

Hyperliquid’s daily Relative Strength Index, positioned at 28.75, indicates an oversold market experiencing heavy short-term selling pressure. While an oversold RSI confirms strong immediate bearish momentum, the selling force could soon face exhaustion. As the macro trend remains bearish, the asset is deeply overstretched and highly primed for consolidation.

The Moving Average Convergence Divergence line of $HYPE is below the signal line; sellers are accelerating the short-term downward price momentum. With both lines below the zero line, the long-term market structure is dominated by the bears. This is a definitive bearish continuation signal, showing a deeply rooted downtrend with aggressive underlying distribution.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

AstraZeneca invests $2 billion in Summit, optimistic about Akeso's Ivose

This 18.6% premium subscription is not only a substantial endorsement, but both parties will also deeply collaborate on the joint development of combination therapies such as ADCs. The core of this deal is Akeso's Ivonescimab—the world’s first PD-1/VEGF bispecific antibody, and so far the only drug to have surpassed "K-drug" in head-to-head trials on both PFS and OS endpoints. The median OS reached 30.8 months, compared to 22.6 months for "K-drug", representing a 27% reduction in risk of death.

华尔街见闻•2026/09/29 00:26

AMD (AMD.US) Surpasses $1 Trillion Market Cap and Begins Competing for "Computing Power Definition Rights"! Officially Announces $8.2 Billion Acquisition of Fei-Fei Li's World Labs

AMD has agreed to acquire World Labs for $8.2 billion, thereby gaining access to the artificial intelligence startup founded by industry pioneer and researcher Fei-Fei Li. This acquisition is expected to help AMD plan its future hardware launches by bringing in a team of top researchers and their models, as well as deep insights into trends in the field of artificial intelligence.

智通财经•2026/09/29 00:06